Desferrioxamine decreases NAD redox potential of intact red blood cells: Evidence for desferrioxamine as an inducer of oxidant stress in red blood cells

BMC Clinical Pharmacology

Volumn 2, Issue , 2002, Pages

  Niihara, Yutaka ^a   Ge, Junli ^a   Shalev, Oded ^b   Wu, Huiyuan ^a   Tu, Amy ^a   Tanaka, Kouichi R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Desferrioxamine; Iron; NAD redox potential; Oxidant stress; Red blood cells

Indexed keywords

DEFEROXAMINE; FERRIC ION; IRON CHELATING AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; XENOBIOTIC AGENT;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHROCYTE; EVIDENCE BASED MEDICINE; HUMAN; HUMAN EXPERIMENT; INCUBATION TIME; INFLAMMATION; NORMAL HUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PROTEIN FUNCTION; SICKLE CELL ANEMIA; THALASSEMIA; TISSUE INJURY; CLINICAL TRIAL; DRUG EFFECT; METABOLISM; OXIDATION REDUCTION REACTION;

DEFEROXAMINE; ERYTHROCYTES; HUMANS; IRON CHELATING AGENTS; NAD; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 2942612295     PISSN: 14726904     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-2-8     Document Type: Article

References (21)

1. Goodwin JF, Whitten CF: Chelation of ferrous sulphate solutions by desferrioxamine B. Nature 1965, 205:281(Abstr)
2. Blake DR, Hall ND, Bacon PA, Dieppe PA, Halliwell B, Gutteridge JM: Effect of a specific iron chelating agent on animal models of inflammation. Ann Rheum Dis 1983, 42:89-93
3. Hamilton KO, Stallibrass L, Hassan I, Jin Y, Halleux C, Mackay M: The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers. Br J Haematol 1994, 86:851-7
4. Minotti G, Aust SD: The role of iron in the initiation of lipid peroxidation. Chem Phys Lipids 1987, 44:191-208
5. Rachidi S, Coudray C, Baret P, Gelon G, Pierre JL, Favier A: Inhibition of lipid peroxidation by a new family of iron chelators. Comparison with desferrioxamine. Biol Trace Elem Res 1994, 41:77-87
6. Winterbourn CC, Vile GF, Monteiro HP: Ferritin, lipid peroxidation and redox-cycling xenobiotics. Free Radic Res Commun 1991, 12-13(Pt 1):107-14
7. Klebanoff SJ, Waltersdorph AM, Michel BR, Rosen H: Oxygen-based free radical generation by ferrous ions and deferoxamine. J Biol Chem 1989, 264:19765-71
8. Mordente A, Meucci E, Miggiano GA, Martorana GE: Prooxidant action of desferrioxamine: enhancement of alkaline phosphatase inactivation by interaction with ascorbate system. Arch Biochem Biophys 1990, 277:234-40
9. Blake DR, Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JM, Rowley D, Halliwell B, Cornish A, et al: Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 1985, 56:345-55
10. Davies MJ, Donkor R, Dunster CA, Gee CA, Jonas S, Willson RL: Desferrioxamine (Desferal) and superoxide free radicals. Formation of an enzyme-damaging nitroxide. Biochem J 1987, 246:725-9
11. Yoshino S, Blake DR, Bacon PA: The effect of desferrioxamine on antigen-induced inflammation in the rat air pouch. J Pharm Pharmacol 1984, 36:543-5
12. Bergamini S, Rota C, Staffieri M, Tomasi A, Iannone A: Prooxidant activity of ferrioxamine in isolated rat hepatocytes and linoleic acid micelles. Chem Res Toxicol 1999, 12:365-70
13. Niihara Y, Shalev O, Hebbel RP, Wu H, Tu A, Akiyama DS, Tanaka KR: Desferrioxamine (DFO) conjugated with starch decreases NAD redox potential of intact red blood cells (RBC): evidence for DFO as an extracellular inducer of oxidant stress in RBC. Am J Hematol 2000, 65:281-4
14. Zerez CR, Lee SJ, Tanaka KR: Spectrophotometric determination of oxidized and reduced pyridine nucleotides in erythrocytes using a single extraction procedure. Anal Biochem 1987, 164:367-73
15. Niihara Y, Zerez CR, Akiyama DS, Tanaka KR: Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol 1998, 58:117-21
16. Jaffe ER, Hultquist DE: Metabolic and Molecular Basis of Inherited Disease. Cytochrome b5 reductase deficiency and enzymopenic hereditary methemoglobinemia. New York, McGraw-Hill (Edited by: CR Scriver, AL Beaudet, WS Sly, D Valle)1995, 3399-3415
17. Gutteridge JM, Paterson SK, Segal AW, Halliwell B: Inhibition of lipid peroxidation by the iron-binding protein lactoferrin. Biochem J 1981, 199:259-61
18. Wills ED: Mechanisms of lipid peroxide formation in animal tissues. Biochem J 1966, 99:667-76
19. Hinojosa O, Jacks TJ, Calamari TA, Thibodeaux DP: Electron spin resonance study of the relationship of UV irradiation to nitroxide radical formation in desferrioxamine (Desferal) and related hydroxamate and hydroxylamine derivatives. Photochem Photobiol 1989, 49:1-5
20. Borg DC, Schaich KM: Prooxidant action of desferrioxamine: Fenton-like production of hydroxyl radicals by reduced ferrioxamine. J Free Radic Biol Med 1986, 2:237-43
21. Morehouse KM, Flitter WD, Mason RP: The enzymatic oxidation of Desferal to a nitroxide free radical. FEBS Lett 1987, 222:246-50